Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

SK Life Science launched its latest DTC advertising campaign for its seizure medication. 1 Road to Reduction is an ...

With uncertainty surrounding the future of government funding, the onus is being placed on the private sector to continue ...

Supernus Pharmaceuticals’ campaign aims to raise awareness about issues women face even getting diagnosed with ADHD.

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Lilly is also developing oral therapies for its gastroenterology pipeline.

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses the company's nationwide push to reduce cardiovascular risk ...

Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically ...

Positive feedback was based on Phase III AQUILA trial results, which showed a significant clinical benefit with Darzalex Faspro in patients with high-risk smoldering multiple myeloma.